Ryman HealthcareNZSE:RYM -0.44%70 Median PS Value is NZ$0.00 as of Jun. 28, 2026. GuruFocus rates NZSE:RYM with a GF Score™ of 70/100 (Possible Value Trap). Among 262 Healthcare Providers & Services companies, Ryman Healthcare ranks better than 96.56% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Ryman Healthcare's Median PS Value or its related term are showing as below:
NZSE:RYM's Price-to-Median-PS-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.69 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Ryman Healthcare (NZSE:RYM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Ryman Healthcare's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.28
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryman Healthcare Median PS Value Related Terms
Ryman Healthcare Median PS Value Historical Data
* Premium members only.
The historical data trend for Ryman Healthcare's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:RYM vs HCA, THC, DVA: Median PS Value Comparison
For the Medical Care Facilities subindustry, Ryman Healthcare's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryman Healthcare Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ryman Healthcare's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Ryman Healthcare's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ryman Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was NZ$1.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryman Healthcare (NZSE:RYM) has a Median PS Value of NZ$0.00 as of Jun. 28, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Ryman Healthcare and its competitors. According to the industry distribution chart, Ryman Healthcare ranks #9 out of 262 companies in the Healthcare Providers & Services industry, placing it in the top 3.4%.
Is Ryman Healthcare's Median PS Value too high?
Ryman Healthcare's current Median PS Value is NZ$0.00. Based on the distribution chart, Ryman Healthcare ranks #9 out of 262 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Ryman Healthcare has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryman Healthcare's Median PS Value compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ryman Healthcare ranks #9 out of 262 companies for Median PS Value. This places Ryman Healthcare in the top 3% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.69, based on 262 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Ryman Healthcare and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryman Healthcare's current Median PS Value is NZ$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryman Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Ryman Healthcare (NZSE:RYM) is currently considered Possible Value Trap. The current Median PS Value is NZ$0.00. Ryman Healthcare's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Ryman Healthcare (NZSE:RYM), the current Median PS Value is NZ$0.00 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ryman Healthcare Ltd is a retirement living and aged care provider operating in New Zealand and Australia. It owns and operates integrated retirement villages through its trading subsidiaries, which operate in the aged care and retirement living sector in New Zealand and Australia. The Group operates in a single industry: the provision of integrated retirement living and aged care for older people in New Zealand and Australia. The majority of revenue is derived from Care and village fees, which relate to the provision of accommodation, care and related services to aged care residents and retirement living residents.
70GF Score
Get the complete analysis for NZSE:RYM
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:RYM has been successfully added to your 
